Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas.

Sixty-nine unselected patients with locally advanced and metastatic carcinoma of the pancreas, who had not received previous chemotherapy or radiotherapy were randomised to receive either 5-fluorouracil, epirubicin and mitomycin C (FEM) or epirubicin. Survival was not significantly different in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Topham, C., Glees, J., Rawson, N. S., Woods, E. M., Coombes, R. C.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1991
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977308/
https://www.ncbi.nlm.nih.gov/pubmed/1906726
_version_ 1782135234213445632
author Topham, C.
Glees, J.
Rawson, N. S.
Woods, E. M.
Coombes, R. C.
author_facet Topham, C.
Glees, J.
Rawson, N. S.
Woods, E. M.
Coombes, R. C.
author_sort Topham, C.
collection PubMed
description Sixty-nine unselected patients with locally advanced and metastatic carcinoma of the pancreas, who had not received previous chemotherapy or radiotherapy were randomised to receive either 5-fluorouracil, epirubicin and mitomycin C (FEM) or epirubicin. Survival was not significantly different in the two arms. Toxic reactions (WHO grade greater than 3) in the FEM and epirubicin arm respectively included nausea (2), (4), severe alopecia (1) (3) and leucopenia (1), (5), none of these were statistically significant. We therefore suggest that combination chemotherapy should not be used in preference to single agent chemotherapy as standard treatment for locally advanced or metastatic cancer of the pancreas.
format Text
id pubmed-1977308
institution National Center for Biotechnology Information
language English
publishDate 1991
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19773082009-09-10 Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas. Topham, C. Glees, J. Rawson, N. S. Woods, E. M. Coombes, R. C. Br J Cancer Research Article Sixty-nine unselected patients with locally advanced and metastatic carcinoma of the pancreas, who had not received previous chemotherapy or radiotherapy were randomised to receive either 5-fluorouracil, epirubicin and mitomycin C (FEM) or epirubicin. Survival was not significantly different in the two arms. Toxic reactions (WHO grade greater than 3) in the FEM and epirubicin arm respectively included nausea (2), (4), severe alopecia (1) (3) and leucopenia (1), (5), none of these were statistically significant. We therefore suggest that combination chemotherapy should not be used in preference to single agent chemotherapy as standard treatment for locally advanced or metastatic cancer of the pancreas. Nature Publishing Group 1991-07 /pmc/articles/PMC1977308/ /pubmed/1906726 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Topham, C.
Glees, J.
Rawson, N. S.
Woods, E. M.
Coombes, R. C.
Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas.
title Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas.
title_full Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas.
title_fullStr Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas.
title_full_unstemmed Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas.
title_short Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas.
title_sort randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin c in locally advanced and metastatic carcinoma of the pancreas.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977308/
https://www.ncbi.nlm.nih.gov/pubmed/1906726
work_keys_str_mv AT tophamc randomisedtrialofepirubicinaloneversus5fluorouracilepirubicinandmitomycincinlocallyadvancedandmetastaticcarcinomaofthepancreas
AT gleesj randomisedtrialofepirubicinaloneversus5fluorouracilepirubicinandmitomycincinlocallyadvancedandmetastaticcarcinomaofthepancreas
AT rawsonns randomisedtrialofepirubicinaloneversus5fluorouracilepirubicinandmitomycincinlocallyadvancedandmetastaticcarcinomaofthepancreas
AT woodsem randomisedtrialofepirubicinaloneversus5fluorouracilepirubicinandmitomycincinlocallyadvancedandmetastaticcarcinomaofthepancreas
AT coombesrc randomisedtrialofepirubicinaloneversus5fluorouracilepirubicinandmitomycincinlocallyadvancedandmetastaticcarcinomaofthepancreas

Ejemplares similares